Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western countries. It is characterized by the progressive accumulation of mature-appearing yet immunologically dysfunctional B ...

Despite the emergence of more effective treatments, mainly the combination of immunotherapy with fludarabine-based regimens, CLL remains incurable. These more intensive therapies achieve the ...

Recent advances in the treatment of patients with CLL have achieved promising results, at least in fit patients who can tolerate the more intensive immunochemotherapic regimens. New combinations ...

Multiple steps are involved in the pathogenesis of chronic lymphocytic leukemia (CLL) and various factors are related to its development: cytogenetic aberrations, antigenic triggers activated by ...

In separate, live virtual events, Alvaro Jose Alencar, MD, and Michael E. Williams, MD, discussed third-line options for a patient with relapsed/refractory chronic lymphocytic leukemia (CLL).

In an interview, Paolo Ghia, MD, PhD, discussed updated data from the phase 2 CAPTIVATE trial of ibrutinib and venetoclax in ...

Panelists discuss how challenges in implementing emerging Bruton tyrosine kinase inhibitor (BTKi) regimens for ...

New data suggest venetoclax may offset the negative prognostic impact of short telomeres in patients with chronic lymphocytic ...

Leukemia symptoms can vary by the cancer stage and type of leukemia you have. In the early stages, leukemia symptoms like fatigue, fever, and bruising can be subtle and easily dismissed. But, as the ...

Tafasitamab (MOR-208, XmAb5574) is under development for the treatment of B cell malignancies including relapsed or refractory non-Hodgkin lymphoma, relapsed or refractory chronic lymphocytic leukemia ...

Leukemias and lymphomas are often grouped together because they are both blood-related cancers that originate in lymphocytes. However, leukemia originates in the bone marrow and spreads through the ...

Cardiovascular management strategies are essential to individuals with chronic lymphocytic leukemia (CLL) or multiple myeloma (MM) undergoing active treatment, due to the high rate of atrial ...